Bilgen, TürkerCanbakan, MustafaŞahin, G.Titiz, Mesut İzzet2022-05-112022-05-1120190041-1345https://doi.org/10.1016/j.transproceed.2019.01.099https://hdl.handle.net/20.500.11776/4497Cytotoxic flow cytometric crossmatch (cFCXM), identified by detecting complement-mediated cytotoxic cell death in addition to the capability of showing the alloantibodies binding onto lymphocytes at the same time, can reduce the necessary time and workload in evaluating alloantibodies. More data from clinical samples are needed for cFCXM to be accepted by tissue typing laboratories. In this study, we compared cFCXM with complement-dependent lymphocytotoxicity and standard flow cytometric crossmatch in 41 renal pretransplant patients. A comparison of the obtained data was performed using Spearman's correlation test. We found that cFCXM showed no statistically significant differences with complement-dependent lymphocytotoxicity and flow cytometric crossmatch. We believe that cFCXM can be used in clinical laboratories in the near future following intra-laboratory validation. © 2019 Elsevier Inc.en10.1016/j.transproceed.2019.01.099info:eu-repo/semantics/closedAccessArticleblood examinationclinical laboratorycomplement dependent lymphocytotoxicitycontrolled studycorrelation coefficientcytotoxic flow cytometric crossmatchcytotoxicity testflow cytometric crossmatchflow cytometrygraft recipienthumanhuman cellintermethod comparisonkidney transplantationpriority journalcomparative studycytotoxicity testfemaleflow cytometryhistocompatibility testimmunologykidney transplantationmaleproceduresalloantibodyCytotoxicity Tests, ImmunologicFemaleFlow CytometryHistocompatibility TestingHumansIsoantibodiesKidney TransplantationMaleArticle51410211023Q4WOS:0005001793000032-s2.0-8506557877831101163Q3